[refurb]

As someone who works in the industry, the article was a 30,000 ft view and didn’t do a good job of digging into the issue.

Regardless, it looks like the drug does reduce pancreatitis attacks, but only by 50%. So it certainly doesn’t “cure” the patient.

The clinical trials were also quite small, so possibly the national payers said “$1M is reasonable if you do X, but you don’t have the data to convince me you can do X.”